Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets

Expert Review of Vaccines

Volumn 12, Issue 4, 2013, Pages 365-378

  De Cassan, Simone C ^a   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

adenovirus; adjuvant; antibody; B cell; DNA vaccine; poxvirus; prime boost; protein vaccine; T cell; viral vector vaccine

Indexed keywords

ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; MALARIA VACCINE; ORTHOPOXVIRUS VACCINE; SUBUNIT VACCINE; VIRUS VECTOR;

CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; FOWLPOX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE SUBPOPULATION; MALARIA FALCIPARUM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

ADENOVIRIDAE; AIDS VACCINES; ANTIBODIES, PROTOZOAN; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; POXVIRIDAE; VACCINATION;

EID: 84875931857     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.11     Document Type: Review

References (153)

1. Hill AV. Vaccines against malaria. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366(1579), 2806-2814 (2011).
2. McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat. Immunol. 13(5), 423-427 (2012).
3. Vasan S, Michael NL. Improved outlook on HIV-1 prevention and vaccine development. Expert Opin. Biol. Ther. 12(8), 983-994 (2012).
4. Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr. Opin. Immunol. 24(3), 310-315 (2012).
5. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8(1), 62-73 (2010).
6. Bråve A, Ljungberg K, Wahren B, Liu MA. Vaccine delivery methods using viral vectors. Mol. Pharm. 4(1), 18-32 (2007).
7. Liu MA. Immunologic basis of vaccine vectors. Immunity 33(4), 504-515 (2010).
8. Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25(1), 21-28 (1983). (Pubitemid 14241202)
9. Orubu T, Alharbi NK, Lambe T, Gilbert SC, Cottingham MG. Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS ONE 7(6), e40167 (2012).
10. Tine JA, Lanar DE, Smith DM et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 64(9), 3833-3844 (1996). (Pubitemid 26298712)
11. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12(8), 557-569 (2012).
12. Kuballa P, Nolte WM, Castoreno AB, Xavier RJ. Autophagy and the immune system. Annu. Rev. Immunol. 30, 611-646 (2012).
13. Huang X, Yang Y. Innate immune recognition of viruses and viral vectors. Hum. Gene Ther. 20(4), 293-301 (2009).
14. Delaloye J, Roger T, Steiner-Tardivel QG et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5(6), e1000480 (2009).
15. Querec T, Bennouna S, Alkan S et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203(2), 413-424 (2006). (Pubitemid 43290850)
16. Appledorn DM, Patial S, McBride A et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 181(3), 2134-2144 (2008).
17. Johnson MJ, Petrovas C, Yamamoto T et al. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J. Immunol. 188(12), 6109-6118 (2012).
18. Rhee EG, Blattman JN, Kasturi SP et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J. Virol. 85(1), 315-323 (2011).
19. Yang H, Wu H, Hancock G et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J. Infect. Dis. 206(4), 552-561 (2012).
20. Soghoian DZ, Jessen H, Flanders M et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med. 4(123), 123ra25 (2012).
21. Fellay J, Shianna KV, Ge D et al. A wholegenome association study of major determinants for host control of HIV-1. Science 317(5840), 944-947 (2007). (Pubitemid 47301321)
22. Hill AV, Allsopp CE, Kwiatkowski D et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 352(6336), 595-600 (1991). (Pubitemid 21912384)
23. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165(3), 1453-1462 (2000). (Pubitemid 30604578)
24. Schmidt NW, Butler NS, Badovinac VP, Harty JT. Extreme CD8+ T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog. 6(7), e1000998 (2010).
25. Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4(4), 397-402 (1998). (Pubitemid 28212753)
26. O'Hara GA, Duncan CJ, Ewer KJ et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205(5), 772-781 (2012).
27. Moorthy VS, Imoukhuede EB, Keating S et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189(12), 2213-2219 (2004). (Pubitemid 38757193)
28. Song K, Bolton DL, Wei CJ et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc. Natl Acad. Sci. USA 107(51), 22213-22218 (2010).
29. Reyes-Sandoval A, Wyllie DH, Bauza K et al. CD8+ T effector memory cells protect against liver-stage malaria. J. Immunol. 187(3), 1347-1357 (2011).
30. Paris RM, Kim JH, Robb ML, Michael NL. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev. Vaccines 9(9), 1055-1069 (2010).
31. McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9(6), 729-735 (2003). (Pubitemid 36749222)
32. Webster DP, Dunachie S, Vuola JM et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Acad. Sci. USA 102(13), 4836-4841 (2005). (Pubitemid 40471540)
33. Tamminga C, Sedegah M, Regis D et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS ONE 6(10), e25868 (2011).
34. Schuldt NJ, Amalfitano A. Malaria vaccines: focus on adenovirus based vectors. Vaccine 30(35), 5191-5198 (2012).
35. Koup RA, Roederer M, Lamoreaux L et al.; VRC 009 Study Team; VRC 010 Study Team. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS ONE 5(2), e9015 (2010).
36. Churchyard GJ, Morgan C, Adams E et al.; NIAID HIV Vaccine Trials Network. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS ONE 6(8), e21225 (2011).
37. Jaoko W, Karita E, Kayitenkore K et al. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS ONE 5(9), e12873 (2010).
38. Hill AV, Reyes-Sandoval A, O'Hara G et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6(1), 78-83 (2010).
39. Bruña-Romero O, González-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl Acad. Sci. USA 98(20), 11491-11496 (2001). (Pubitemid 32928756)
40. Goodman AL, Epp C, Moss D et al. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect. Immun. 78(11), 4601-4612 (2010).
41. Lemckert AA, Sumida SM, Holterman L et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol. 79(15), 9694-9701 (2005). (Pubitemid 41022312)
42. Liu J, O'Brien KL, Lynch DM et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457(7225), 87-91 (2009).
43. Barnes E, Folgori A, Capone S et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 4(115), 115ra1 (2012).
44. Dudareva M, Andrews L, Gilbert SC et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27(27), 3501-3504 (2009).
45. Colloca S, Barnes E, Folgori A et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4(115), 115ra2 (2012).
46. Roestenberg M, Remarque E, de Jonge E et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE 3(12), e3960 (2008).
47. Wu Y, Ellis RD, Shaffer D et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 3(7), e2636 (2008).
48. de Cassan SC, Forbes EK, Douglas AD et al. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J. Immunol. 187(5), 2602-2616 (2011).
49. Agger EM, Rosenkrands I, Hansen J et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 3(9), e3116 (2008).
50. Goodman AL, Draper SJ. Blood-stage malaria vaccines -recent progress and future challenges. Ann. Trop. Med. Parasitol. 104(3), 189-211 (2010).
51. Draper SJ, Moore AC, Goodman AL et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 14(8), 819-821 (2008).
52. Reyes-Sandoval A, Sridhar S, Berthoud T et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol. 38(3), 732-741 (2008).
53. Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, Draper SJ. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28(44), 7167-7178 (2010).
54. Draper SJ, Goodman AL, Biswas S et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody-and T cell-mediated multistage protection against malaria. Cell Host Microbe 5(1), 95-105 (2009).
55. Biswas S, Spencer AJ, Forbes EK et al. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection. J. Immunol. 188(10), 5041-5053 (2012).
56. Bruder JT, Stefaniak ME, Patterson NB et al. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 28(18), 3201-3210 (2010).
57. Zong S, Kron MW, Epp C et al. ?E1 and high-capacity adenoviral vectors expressing full-length codon-optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum. J. Gene Med. 13(12), 670-679 (2011).
58. Miura K, Zhou H, Diouf A et al. Antiapical-membrane-antigen-1 antibody is more effective than anti-42-kilodaltonmerozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin. Vaccine Immunol. 16(7), 963-968 (2009).
59. Biswas S, Dicks MD, Long CA et al. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS ONE 6(6), e20977 (2011).
60. Draper SJ, Biswas S, Spencer AJ et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol. 185(12), 7583-7595 (2010).
61. Goodman AL, Blagborough AM, Biswas S et al. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity. PLoS ONE 6(12), e29428 (2011).
62. Yang S, Carroll MW, Torres-Duarte AP, Moss B, Davidson EA. Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus. Vaccine 15(12-13), 1303-1313 (1997). (Pubitemid 27397804)
63. Douglas AD, Williams AR, Illingworth JJ et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2, 601 (2011).
64. Baum J, Chen L, Healer J et al. Reticulocyte-binding protein homologue 5 -an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int. J. Parasitol. 39(3), 371-380 (2009).
65. Rodriguez M, Lustigman S, Montero E, Oksov Y, Lobo CA. PfRH5: a novel reticulocyte-binding family homolog of Plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. PLoS ONE 3(10), e3300 (2008).
66. Santra S, Seaman MS, Xu L et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79(10), 6516-6522 (2005). (Pubitemid 40617255)
67. Mascola JR, Sambor A, Beaudry K et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 79(2), 771-779 (2005). (Pubitemid 40053860)
68. Seaman MS, Xu L, Beaudry K et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79(5), 2956-2963 (2005). (Pubitemid 40270574)
69. Barouch DH, Liu J, Li H et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482(7383), 89-93 (2012).
70. Letvin NL, Rao SS, Montefiori DC et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 3(81), 81ra36 (2011).
71. Lai L, Kwa S, Kozlowski PA et al. Prevention of infection by a granulocytemacrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J. Infect. Dis. 204(1), 164-173 (2011).
72. Catanzaro AT, Koup RA, Roederer M et al.; Vaccine Research Center 006 Study Team. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194(12), 1638-1649 (2006). (Pubitemid 44901994)
73. Catanzaro AT, Roederer M, Koup RA et al.; VRC 007 Study Team. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25(20), 4085-4092 (2007). (Pubitemid 46616987)
74. Graham BS, Koup RA, Roederer M et al.; Vaccine Research Center 004 Study Team. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194(12), 1650-1660 (2006). (Pubitemid 44901995)
75. Koblin BA, Casapia M, Morgan C et al.; NIAID HIV Vaccine Trials Network. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS ONE 6(9), e24517 (2011).
76. Buchbinder SP, Mehrotra DV, Duerr A et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
77. Duerr A, Huang Y, Buchbinder S et al.; Step/HVTN 504 Study Team. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J. Infect. Dis. 206(2), 258-266 (2012).
78. Keefer MC, Gilmour J, Hayes P et al. A Phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS ONE 7(8), e41936 (2012).
79. Sheehy SH, Duncan CJ, Elias SC et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 7(2), e31208 (2012).
80. Sheehy SH, Duncan CJ, Elias SC et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. 19(12), 2269-2276 (2011).
81. Sedegah M, Tamminga C, McGrath S et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS ONE 6(10), e24586 (2011).
82. Pierce MA, Ellis RD, Martin LB et al. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 28(10), 2236-2242 (2010).
83. Malkin EM, Diemert DJ, McArthur JH et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual bloodstage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73(6), 3677-3685 (2005). (Pubitemid 40745912)
84. Ellis RD, Mullen GE, Pierce M et al. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 27(31), 4104-4109 (2009).
85. Sheehy SH, Duncan CJ, Elias SC et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20(12), 2355-2368 (2012).
86. Dutta S, Sullivan JS, Grady KK et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE 4(12), e8138 (2009).
87. Lyon JA, Angov E, Fay MP et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS ONE 3(7), e2830 (2008).
88. Cheru L, Wu Y, Diouf A et al. The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine 28(27), 4423-4429 (2010).
89. Saul A. Kinetic constraints on the development of a malaria vaccine. Parasite Immunol. 9(1), 1-9 (1987). (Pubitemid 17026564)
90. Thera MA, Doumbo OK, Coulibaly D et al. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365(11), 1004-1013 (2011).
91. Spring MD, Cummings JF, Ockenhouse CF et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4(4), e5254 (2009).
92. Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J. Clin. Invest. 120(10), 3688-3701 (2010).
93. Palma C, Overstreet MG, Guedon JM et al. Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoiteneutralizing antibodies in mice. Vaccine 29(8), 1683-1689 (2011).
94. Worgall S, Krause A, Rivara M et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J. Clin. Invest. 115(5), 1281-1289 (2005). (Pubitemid 40629047)
95. Sridhar S, Reyes-Sandoval A, Draper SJ et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J. Virol. 82(8), 3822-3833 (2008). (Pubitemid 351521219)
96. Forbes EK, de Cassan SC, Llewellyn D et al. T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein. PLoS ONE 7(9), e44943 (2012).
97. Li X, Fujio M, Imamura M et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc. Natl Acad. Sci. USA 107(29), 13010-13015 (2010).
98. Ophorst OJ, Radosevic K, Klap JM et al. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 25(35), 6501-6510 (2007). (Pubitemid 47198919)
99. Kyriakis CS, De Vleeschauwer A, Barbé F, Bublot M, Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine 27(16), 2258-2264 (2009).
100. Ganne V, Eloit M, Laval A, Adam M, Trouve G. Enhancement of the efficacy of a replication-defective adenovirus-vectored vaccine by the addition of oil adjuvants. Vaccine 12(13), 1190-1196 (1994). (Pubitemid 24293239)
101. Minke JM, Fischer L, Baudu P et al. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet. Immunol. Immunopathol. 111(1-2), 47-57 (2006).
102. Wang R, Epstein J, Charoenvit Y et al. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J. Immunol. 172(9), 5561-5569 (2004). (Pubitemid 38542058)
103. Miao J, Li X, Liu Z, Xue C, Bujard H, Cui L. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines. Vaccine 24(37-39), 6187-6198 (2006). (Pubitemid 44247247)
104. Vinner L, Therrien D, Wee E et al. Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1. APMIS 114(10), 690-699 (2006). (Pubitemid 44483957)
105. Shu Y, Winfrey S, Yang ZY et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25(8), 1398-1408 (2007). (Pubitemid 46074300)
106. Patterson LJ, Malkevitch N, Pinczewski J et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hrsimian immunodeficiency virus (SIV) env/ rev, gag, and/or nef vaccines and boosted with SIV gp120. J. Virol. 77(16), 8607.
107. Gómez-Román VR, Florese RH, Peng B et al. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibodydependent cellular cytotoxicity against non-subtype B HIV strains. J. Acquir. Immune Defic. Syndr. 43(3), 270-277 (2006). (Pubitemid 44674006)
108. Hutchings CL, Birkett AJ, Moore AC, Hill AV. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect. Immun. 75(12), 5819-5826 (2007). (Pubitemid 350207821)
109. Hutchings CL, Gilbert SC, Hill AV, Moore AC. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J. Immunol. 175(1), 599-606 (2005). (Pubitemid 40884366)
110. Bouillet LÉ, Dias MO, Dorigo NA et al. Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen protein prime/adenovirus boost immunization protocol. Infect. Immun. 79(9), 3642-3652 (2011).
111. Radosevic K, Rodriguez A, Lemckert AA et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin. Vaccine Immunol. 17(11), 1687-1694 (2010).
112. Stewart VA, McGrath SM, Dubois PM et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75(5), 2283-2290 (2007). (Pubitemid 46744316)
113. Dunachie SJ, Walther M, Vuola JM et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24(15), 2850-2859 (2006).
114. Cadoz M, Strady A, Meignier B et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339(8807), 1429-1432 (1992).
115. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).
116. Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366(14), 1275-1286 (2012).
117. Smith GL, Mackett M, Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302(5908), 490-495 (1983). (Pubitemid 13111130)
118. Kreijtz JH, Suezer Y, de Mutsert G et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J. Infect. Dis. 199(3), 405-413 (2009).
119. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12(11), 1032-1040 (1994).
120. Wang Z, La Rosa C, Maas R et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J. Virol. 78(8), 3965-3976 (2004). (Pubitemid 38437202)
121. Weyer J, Rupprecht CE, Nel LH. Poxvirus-vectored vaccines for rabies -a review. Vaccine 27(51), 7198-7201 (2009).
122. Chen Z, Zhang L, Qin C et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79(5), 2678-2688 (2005). (Pubitemid 40270546)
123. Geiben-Lynn R, Greenland JR, Frimpong-Boateng K, Letvin NL. Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia Ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses. Clin. Vaccine Immunol. 15(4), 691-696 (2008). (Pubitemid 351967048)
124. Cubillos-Zapata C, Guzman E, Turner A et al. Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo. J. Virol. 85(18), 9385-9394 (2011).
125. Hensley SE, Cun AS, Giles-Davis W et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol. Ther. 15(2), 393-403 (2007). (Pubitemid 46111891)
126. Forsell MN, McInerney GM, Dosenovic P et al. Increased human immunodeficiency virus type 1 Env expression and antibody induction using an enhanced alphavirus vector. J. Gen. Virol. 88(Pt 10), 2774-2779 (2007). (Pubitemid 47555032)
127. Tatsis N, Fitzgerald JC, Reyes-Sandoval A et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110(6), 1916-1923 (2007). (Pubitemid 47443905)
128. Ronan EO, Lee LN, Beverley PC, Tchilian EZ. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS ONE 4(12), e8235 (2009).
129. Hornemann S, Harlin O, Staib C et al. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J. Virol. 77(15), 8394-8407 (2003). (Pubitemid 36871468)
130. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19(2), 225-234 (2003). (Pubitemid 37011337)
131. Wrammert J, Koutsonanos D, Li GM et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208(1), 181-193 (2011).
132. Chootong P, Ntumngia FB, VanBuskirk KM et al. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect. Immun. 78(3), 1089-1095 (2010).
133. Khurana S, Verma N, Yewdell JW et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3(85), 85ra48 (2011).
134. Wiley SR, Raman VS, Desbien A et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3(93), 93ra69 (2011).
135. Pollard AJ, Hill AV. Antibody repertoire: embracing diversity. Sci. Transl. Med. 3(93), 93ps32 (2011).
136. Stamatatos L. HIV vaccine design: the neutralizing antibody conundrum. Curr. Opin. Immunol. 24(3), 316-323 (2012).
137. Bonsignori M, Pollara J, Moody MA et al. Antibody-dependent cellular cytotoxicitymediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86(21), 11521-11532 (2012).
138. Gray ES, Madiga MC, Hermanus T et al.; and the CAPRISA002 Study Team. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85(10), 4828-4840 (2011).
139. Wu X, Zhou T, Zhu J et al.; NISC Comparative Sequencing Program. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049), 1593-1602 (2011).
140. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30(5), 423-433 (2012).
141. Johnson PR, Schnepp BC, Zhang J et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15(8), 901-906 (2009).
142. Wu Y, Przysiecki C, Flanagan E et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc. Natl Acad. Sci. USA 103(48), 18243-18248 (2006). (Pubitemid 44871643)
143. Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl Acad. Sci. USA 109(4), 1080-1085 (2012). expanded T follicular helper cells and germinal centers.
144. Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543-547 (2011).
145. Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat. Immunol. 10(4), 385-393 (2009).
146. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, Long CA. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26(2), 193-200 (2008). (Pubitemid 350266126)
147. Pol E, Karlsson R, Roos H et al. Biosensorbased characterization of serum antibodies during development of an anti-IgE immunotherapeutic against allergy and asthma. J. Mol. Recognit. 20(1), 22-31 (2007). (Pubitemid 46160157)
148. Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron. Clin. Pract. 96(3), c88-c95 (2004). (Pubitemid 38453092)
149. Reddy SB, Anders RF, Beeson JG et al. High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria. PLoS ONE 7(2), e32242 (2012).
150. Williams AR, Douglas AD, Miura K et al. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog. 8(11), e1002991 (2012).
151. Ockenhouse CF, Sun PF, Lanar DE et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177(6), 1664-1673 (1998). (Pubitemid 28243593)
152. Dicks MD, Spencer AJ, Edwards NJ et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 7(7), e40385 (2012).
153. ClinicalTrials.gov. www.clinicaltrials.gov